November 21, 2019 11:01 AM EST
News Briefing

Ex-Ed­i­tas CEO Ka­trine Bosley chairs Ar­rakis board; Car­du­ri­on touts Po­laris in­vest­ment

Kathy Wong

Editor

→ Af­ter a sur­prise ex­it from Ed­i­tas Med­i­cine in Jan­u­ary — which left many in shock and the stock plung­ing 21% $ED­IT — ex-CEO Ka­trine Bosley …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

CBER's deputy di­rec­tor de­parts as staff shake­up con­tin­ues

Blue­bird bio to sell to in­vest­ment funds af­ter strug­gling to make mon­ey from gene ther­a­pies

FDA ap­proves first drug to treat ul­tra-rare lipid stor­age dis­ease

Eli Lil­ly stock­piles $548M of oral weight loss drug ahead of launch

Will CRISPR mat­ter?

sponsored

Trust­ed pro­tec­tion: Why the cur­rent meningo­coc­cal vac­ci­na­tion sched­ule shouldn’t change with­out strong ev­i­dence

A service from the Financial Times